Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

host protease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV Protease (4) Virus Protease (8) Bacterial (1) Cathepsin (5) DNA/RNA Synthesis (4) HCV (4) Isotope-Labeled Compounds (1) NOD-like Receptor (NLR) (1) Parasite (2) PIKfyve (1) Proteasome (1) Reference Standards (1) SARS-CoV (16)
By Research Areas:	Infection (18) Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Virus Protease HCV Protease HIV Protease Protease Activated Receptor (PAR) ClpP TMPRSS6 Calpain Serpin Enteropeptidase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10241

Simeprevir 40+ Cited Publications TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-156655A

Olgotrelvir sodium STI-1558 sodium	SARS-CoV Cathepsin Virus Protease	Infection
Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of *coronavirus main protease* (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2** replication and entry into host cells .

HY-163943

UNI418	SARS-CoV PIKfyve	Infection
UNI418 is a dual inhibitor of PIKfyve and PIP5K1C with antiviral activity against SARS-CoV-2 (EC₅₀=1.4 μM). UNI418 blocks ACE2-mediated SARS-CoV-2 viral endocytosis by inhibiting PIP5K1C (IC₅₀=60.1 nM; K_d=61 nM). In addition, UNI418 inhibits the proteolytic activation of proteases regulated by PIKfyve (K_d=0.78 nM) to prevent SARS-CoV-2 from entering host cells .

HY-156655

Olgotrelvir STI-1558	SARS-CoV Virus Protease Cathepsin	Infection
Olgotrelvir (STI-1558) is an orally active dual inhibitor of *coronavirus main protease* (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2** replication and entry into host cells .

HY-E70420

SpeB cysteine protease	Bacterial	Inflammation/Immunology
SpeB cysteine protease is a potent modifier of immunologically important host and bacterial proteins. SpeB cysteine protease degrades streptolysin O (SLO) in extracellular vesicles .

HY-158763

MPI8 TG0205221	SARS-CoV Cathepsin Virus Protease	Infection
MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19 .

HY-158763A

MPI8 TFA TG0205221 TFA	SARS-CoV Cathepsin Virus Protease	Infection
MPI8 (TG0205221) TFA is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 TFA exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 TFA can be used in clinical studies of COVID-19 .

HY-172553

AS-0017445	Virus Protease SARS-CoV	Infection
AS-0017445 is an inhibitor targeting the main protease of both the current coronavirus and the virus that caused the Middle East Respiratory Syndrome (MERS) outbreak. AS-0017445 inhibits the viral protein processing in host cells and thus prevents viral replication .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-14644B

Apilimod hydrochloride STA 5326 hydrochloride; LAM-002A free base hydrochloride; AIT-101 hydrochloride	NOD-like Receptor (NLR)	Infection Inflammation/Immunology
Apilimod (STA 5326) hydrochloride is a PIKFYVE kinase inhibitor that promotes NLRP3 inflammatory vesicle activation and IL-1β secretion. Apilimod hydrochloride has been shown to inhibit host cell proteases, which may prevent viral invasion but also block antiviral immune responses, potentially exacerbating immunosuppression in COVID-19.

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-173459

N-0920	SARS-CoV	Infection
N-0920 is a potent TMPRSS2 inhibitor with an IC₅₀ of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC₅₀s values of 300 pM and 90 pM, respectively .

HY-P5344

Dabcyl-LNKRLLHETQ-Edans Fluorigenic PEXEL peptide	Parasite	Others
Dabcyl-LNKRLLHETQ-Edans (Fluorigenic PEXEL peptide) is a biological active peptide. (This FRET substrate peptide for Plasmepsin V (PMV) is derived from the conserved Plasmodium Export Element (PEXEL) motif of Histidine-Rich Protein II (HRPII). PMV is an ER aspartic protease that recognizes and cleaves the RXL sequence within the PEXEL motif of proteins exported by human malaria parasite Plasmodium falciparum, allowing them to translocate into host erythrocytes.)

HY-N144101

SARS-CoV MPro-IN-2	SARS-CoV	Infection
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-147849

JMI-105	Parasite	Infection
JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQ ^S (3D7; IC₅₀=8.8 µM) and CQ ^R (RKL-9; IC₅₀=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent .

HY-N15365

Antcin B	Virus Protease SARS-CoV	Infection
Antcin B is a SARS-CoV-2 3-chymotrypsin-like protease (3CL Pro) inhibitor. Antcin B binds to multiple key amino acid residues of 3CL Pro(such as Leu141, Asn142, Glu166, His163, etc.) through hydrogen bonds, salt bridges, and hydrophobic interactions, thereby inhibiting the activity of 3CL Pro, blocking the cleavage process of viral polyproteins, and suppressing the replication of the SARS-CoV-2 virus in host cells. Antcin B is promising for research of COVID-19 .

HY-10241R

Simeprevir (Standard) TMC435 (Standard); TMC435350 (Standard)	Reference Standards HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (Standard) is the analytical standard of Simeprevir (HY-10241). This product is intended for research and analytical applications. Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-179612

SARS-CoV-2 3CLpro-IN-34	SARS-CoV Cathepsin Proteasome	Infection
SARS-CoV-2 3CLpro-IN-34 (Compound 55) is a highly efficient non-covalent inhibitor of the SARS-CoV-2 3CL ^pro protease (b. SARS-CoV-2 3CL ^pro protease) with an IC₅₀ of 1.9 μM. SARS-CoV-2 3CLpro-IN-34 can inhibit the 3CL ^pro protein of SARS-CoV-1, with its IC₅₀ being 3.2 μM, and it shows high selectivity towards host cysteine proteases (such as cathepsins L/K and calpain). SARS-CoV-2 3CLpro-IN-34 exhibits antiviral activity in cells infected with SARS-CoV-2, with its EC₅₀ being 25 μM, and it is not affected by P-gp inhibitors and shows no significant cytotoxicity. SARS-CoV-2 3CLpro-IN-34 can be used for research on SARS-CoV-2 infection .

HY-181661

YL1004	SARS-CoV Virus Protease	Infection
YL1004 is a potent, selective and orally active noncovalent inhibitor of *SARS-CoV-2 papain-like protease* (PL ^pro). YL1004 shows an IC₅₀ of 17.5 nM and a K_i of 2.3 nM against PL ^pro, with an in vitro anti-SARS-CoV-2 EC₅₀** of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PL ^pro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection) .

HY-181263

Jun13698	SARS-CoV Virus Protease	Infection
Jun13698 is a SARS-CoV-2 main protease (M ^pro) inhibitor with K_i values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant M ^pro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research .

Cat. No.	Product Name

HY-L940

Antiviral Lead-like compound library	5,813 compounds
Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs. These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance. This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Antiviral Lead-like compound library

5,813 compounds

Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs.

These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance.

This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Cat. No.	Product Name	Target	Research Area

HY-173459

N-0920	SARS-CoV	Infection
N-0920 is a potent TMPRSS2 inhibitor with an IC₅₀ of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC₅₀s values of 300 pM and 90 pM, respectively .

HY-P5528

2Abz-SLGRKIQIK(Dnp)-NH2	Peptides	Others
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)

HY-P5344

Dabcyl-LNKRLLHETQ-Edans Fluorigenic PEXEL peptide	Parasite	Others
Dabcyl-LNKRLLHETQ-Edans (Fluorigenic PEXEL peptide) is a biological active peptide. (This FRET substrate peptide for Plasmepsin V (PMV) is derived from the conserved Plasmodium Export Element (PEXEL) motif of Histidine-Rich Protein II (HRPII). PMV is an ER aspartic protease that recognizes and cleaves the RXL sequence within the PEXEL motif of proteins exported by human malaria parasite Plasmodium falciparum, allowing them to translocate into host erythrocytes.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N144101

SARS-CoV MPro-IN-2	Infection Quinones Classification of Application Fields Plants Lithospermum canescens Lehm. Naphthalene Quinones Disease Research Fields Boraginaceae Source Classification	SARS-CoV
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M ^pro with an IC₅₀ value of 72.07 nM. The main protease (M ^pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .

HY-N15365

Antcin B	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Virus Protease SARS-CoV
Antcin B is a SARS-CoV-2 3-chymotrypsin-like protease (3CL Pro) inhibitor. Antcin B binds to multiple key amino acid residues of 3CL Pro(such as Leu141, Asn142, Glu166, His163, etc.) through hydrogen bonds, salt bridges, and hydrophobic interactions, thereby inhibiting the activity of 3CL Pro, blocking the cleavage process of viral polyproteins, and suppressing the replication of the SARS-CoV-2 virus in host cells. Antcin B is promising for research of COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-10241S

Simeprevir-13C,d3
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks